Grace Therapeutics, Inc.
GRCE
Price:
$3.28
Market Cap:
$46.36M
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Industry
Biotechnology
IPO Date
2012-02-07
Stock Exchange
NASDAQ
Ticker
GRCE
PE Ratio
[-6.19]
ROE
[-12.76%]
Current Ratio
[13.89]
Dividend Yield
[0%]
Enterprise Value
[29.50M]
Dividend History
The ROE as of December 2025 (TTM) for Grace Therapeutics, Inc. (GRCE) is -12.76%
According to Grace Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -12.76%. This represents a change of 269.90% compared to the average of -3.45% of the last 4 quarters.
Grace Therapeutics, Inc. (GRCE) Historical ROE (quarterly & annually)
How has GRCE ROE performed in the past?
The mean historical ROE of Grace Therapeutics, Inc. over the last ten years is -98.45%. The current -12.76% ROE has changed -87.04% with respect to the historical average. Over the past ten years (40 quarters), GRCE's ROE was at its highest in in the September 2019 quarter at 1.68%. The ROE was at its lowest in in the June 2019 quarter at -325.57%.
Average
-98.45%
Median
-29.28%
Minimum
-356.41%
Maximum
-4.98%
Grace Therapeutics, Inc. (GRCE) ROE by Quarter and Year
Discovering the peaks and valleys of Grace Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.03%
Maximum Annual ROE = -4.98%
Minimum Annual Increase = -85.72%
Minimum Annual ROE = -356.41%
| Year | ROE | Change |
|---|---|---|
| 2025 | -14.36% | -31.00% |
| 2024 | -20.82% | -66.66% |
| 2023 | -62.44% | 588.47% |
| 2022 | -9.07% | -74.35% |
| 2021 | -35.35% | -81.99% |
| 2020 | -196.34% | -44.91% |
| 2019 | -356.41% | 36.30% |
| 2018 | -261.49% | 1.03% |
| 2016 | -23.21% | 365.90% |
| 2015 | -4.98% | -85.72% |
Grace Therapeutics, Inc. (GRCE) Average ROE
How has GRCE ROE performed in the past?
The current ROE of Grace Therapeutics, Inc. (GRCE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-32.54%
5-year avg
-28.41%
10-year avg
-98.45%
Grace Therapeutics, Inc. (GRCE) ROE vs. Peers
How is GRCE’s ROE compared to its peers?
Grace Therapeutics, Inc.’s ROE is greater than LAVA Therapeutics N.V. (-106.65%), greater than Tvardi Therapeutics, Inc. (-115.90%), greater than Actinium Pharmaceuticals, Inc. (-151.67%), greater than PDS Biotechnology Corporation (-1.47%), greater than CalciMedica, Inc. (-296.28%), greater than Xilio Therapeutics, Inc. (-618.98%), greater than Lantern Pharma Inc. (-99.88%), greater than OnKure Therapeutics, Inc. (-78.46%), greater than RenovoRx, Inc. (-120.68%), greater than ABVC BioPharma, Inc. (-64.70%),
| Company | ROE | Market cap |
|---|---|---|
| -106.65% | $45.77M | |
| -115.90% | $39.21M | |
| -151.67% | $45.23M | |
| -1.47% | $43.78M | |
| -296.28% | $65.85M | |
| -618.98% | $38.90M | |
| -99.88% | $42.17M | |
| -78.46% | $35.63M | |
| -120.68% | $34.82M | |
| -64.70% | $36.66M |
Build a custom stock screener for Grace Therapeutics, Inc. (GRCE) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Grace Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Grace Therapeutics, Inc. (GRCE) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Grace Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Grace Therapeutics, Inc.'s ROE?
How is the ROE calculated for Grace Therapeutics, Inc. (GRCE)?
What is the highest ROE for Grace Therapeutics, Inc. (GRCE)?
What is the 3-year average ROE for Grace Therapeutics, Inc. (GRCE)?
What is the 5-year average ROE for Grace Therapeutics, Inc. (GRCE)?
How does the current ROE for Grace Therapeutics, Inc. (GRCE) compare to its historical average?